Gilenya® gains EMA approval for pediatric multiple sclerosis
The EMA has approved Gilenya® (fingolimod) for the treatment of children and adolescents with relapsing–remitting forms of multiple sclerosis.
Browsing: fingolimod
Warnings that stopping Gilenya® could make multiple sclerosis worse: industry news round-up
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
